MedTrace Logo

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

NCT04947579 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2024-05-01

Study results available
· View outcomes & findings →

Summary

This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period.

Conditions

  • Spondylitis, Ankylosing

Interventions

DRUG

CC-99677

Oral

OTHER

Placebo

Oral

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb, MD · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-25
Primary Completion
2023-02-21
Completion
2023-02-21
FDA Drug
Yes

Countries

  • United States
  • China
  • Czechia
  • Germany
  • Poland
  • Romania
  • Spain
  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04947579 on ClinicalTrials.gov